# Tailored Vs. Empirical Helicobacter Pylori Infection Treatment

> **NCT06200779** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Manuel Coelho da Rocha** · enrollment: 160 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DIAGNOSTIC_TEST:** Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test
- **DRUG:** Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
- **DRUG:** PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
- **DRUG:** PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days
- **DRUG:** Bismuth quadruple therapy (Pylera®) for 10 days

## Key facts

- **NCT ID:** NCT06200779
- **Lead sponsor:** Manuel Coelho da Rocha
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06200779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06200779, "Tailored Vs. Empirical Helicobacter Pylori Infection Treatment". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT06200779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*